Area of research
Oncology · Pulmonary and Respiratory Medicine
Research interest
Research interests include Cancer Immunotherapy and Biomarkers, Prostate Cancer Treatment and Research, Immunotherapy and Immune Responses, and Cancer Treatment and Pharmacology.
765 NG-350A, a tumor-selective anti-CD40 agonist expressing therapeutic, gemcitabine/nab-paclitaxel and ipilimumab for untreated metastatic pancreatic adenocarcinoma: cohort C of the REVOLUTION trial
Sotigalimab and/or nivolumab with chemotherapy in first-line metastatic pancreatic cancer: clinical and immunologic analyses from the randomized phase 2 PRINCE trial
CD40 agonistic monoclonal antibody APX005M (sotigalimab) and chemotherapy, with or without nivolumab, for the treatment of metastatic pancreatic adenocarcinoma: an open-label, multicentre, phase 1b study
Abstract CT004: A Phase Ib study of CD40 agonistic monoclonal antibody APX005M together with gemcitabine (Gem) and nab-paclitaxel (NP) with or without nivolumab (Nivo) in untreated metastatic ductal pancreatic adenocarcinoma (PDAC) patients